|
|
Association of plasma gelsolin with frailty phenotype and mortality among octogenarian community-dwelling men : a cohort study |
|---|---|
| Author: | Strandberg, Timo E.1,2; Levinson, Susan L.3; DiNubile, Mark J.3; |
| Organizations: |
1Helsinki University Hospital, HUS, University of Helsinki, PO Box 340, FI-00029, Helsinki, Finland 2Center for Life Course Health Research, University of Oulu, Oulu, Finland 3BioAegis Therapeutics Inc, North Brunswick, NJ, USA
4Clinicum, Faculty of Medicine, PO Box 20, FI-00014, Helsinki, Finland
|
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.5 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2022123074125 |
| Language: | English |
| Published: |
Springer Nature,
2022
|
| Publish Date: | 2022-12-30 |
| Description: |
AbstractBackground: Biomarkers are needed for frailty, a common phenotype often associated with muscle loss in older people. Plasma gelsolin (pGSN) is a protein largely synthesized and secreted by skeletal muscle. Aims: To investigate whether pGSN could be a biomarker of the frailty phenotype and predict mortality. Methods: A homogenous cohort of males (born 1919–1934, baseline n = 3490) has been followed since the 1960s. In 2010/11, frailty phenotypes by modified Fried criteria were assessed. pGSN was measured in a convenience subset (n = 469, mean age 83) and re-measured in survivors (n = 127) in 2017. Mortality through December 31, 2018 was retrieved from national registers. Regression models were used for analyses. Results: Of 469 males, 152 (32.4%) were robust, 284 (60.6%) prefrail, and 33 (7.0%) frail in 2010/11. There was a graded (p = 0.018) association between pGSN (mean 58.1 ug/mL, SD 9.3) and frailty. After multivariable adjustment, higher pGSN levels were associated with lower odds of having contemporaneous phenotypic prefrailty (OR per 1 SD 0.73, 95% CI 0.58–0.92) and frailty (OR per 1 SD 0.70, 95% CI 0.44–1.11). By 2018, 179 males (38.2%) had died, and higher baseline pGSN predicted a lower 7-year mortality rate (HR per 1 SD 0.85, 95% CI 0.72–1.00). pGSN concentrations in 2010/11 and 2017 were correlated (n = 127, r = 0.34, p < 0.001). Discussion: Higher baseline pGSN concentrations were associated with a persistently robust phenotype and lower mortality rate over 7 years in a cohort of octogenarian males with high socioeconomic status and may be a promising laboratory biomarker for the development of a frailty phenotype. see all
|
| Series: |
Aging clinical and experimental research |
| ISSN: | 1594-0667 |
| ISSN-E: | 1720-8319 |
| ISSN-L: | 1594-0667 |
| Volume: | 34 |
| Issue: | 5 |
| Pages: | 1095 - 1101 |
| DOI: | 10.1007/s40520-022-02083-2 |
| OADOI: | https://oadoi.org/10.1007/s40520-022-02083-2 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3142 Public health care science, environmental and occupational health 3111 Biomedicine |
| Subjects: | |
| Funding: |
Open Access funding provided by University of Helsinki including Helsinki University Central Hospital. This work was supported by BioAegis Therapeutics, and Helsinki University Hospital (VTR funding; TYH2020126). The analyses were performed independently of the funders. |
| Copyright information: |
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
|
https://creativecommons.org/licenses/by/4.0/ |